Alemtuzumab 治疗多发性硬化后发生噬血细胞综合征：一例报告。
Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
机构信息
Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
出版信息
Mult Scler Relat Disord. 2020 May;40:101973. doi: 10.1016/j.msard.2020.101973. Epub 2020 Jan 31.
BACKGROUND
Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS).
METHODS
We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago.
RESULTS
He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids.
CONCLUSION
HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.
背景
阿仑单抗是一种针对 CD-52 的单克隆抗体，用于治疗复发缓解型多发性硬化症（RRMS）。
方法
我们报告了一例 44 岁男性 RRMS 患者，他在 12 个月前开始接受阿仑单抗治疗后出现发热和黄疸而入院。
结果
他被诊断为噬血细胞综合征（HS）。肝活检显示肝小叶窦状隙库普弗细胞中有噬血细胞现象。治疗包括皮质类固醇治疗。
结论
HS 是一种严重的病症，其特征为免疫系统过度激活，导致快速进行性多器官衰竭，因此在阿仑单抗治疗后出现发热综合征时，需要考虑将其作为鉴别诊断。
Zotero 插件